Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning
2010
Purpose Treosulfan was introduced recently as a conditioning agent for allogeneic blood stem-cell transplantation. The favorable nonhematologic toxicity profile at 3 × 10 g/m2 was the basis for dose escalation in this prospective, multicenter trial. Patients and Methods Fifty-six patients with various hematologic malignancies who were not eligible for standard conditioning were treated with one of three doses: 10 g/m2, 12 g/m2, or 14 g/m2 of intravenous treosulfan, which was administered on days −6 to −4 combined with fludarabine 30 mg/m2 on days −6 to −2. Patients in complete remission (CR; 42%) or non-CR (58%) received grafts from matched related (47%) or matched unrelated (51%) donors; one patient had a mismatched related donor (2%). Results No engraftment failure occurred. Overall, extramedullary toxicity and the nonrelapse mortality rate at 2 years (20%) were low and did not increase with dose. Cumulative incidence of relapse/progression reached 31%. The overall survival and progression-free survival...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
45
References
61
Citations
NaN
KQI